Skip to content
Catalyst

ATPWhat was measured

Measured, with no finding

125 endpoints

Show what was measuredHide what was measured
  • muscular strength (1RM and repetitions to fatigue at 70% of 1RM) and Wingate 30 s anaerobic power (peak PO, total work, average PO), after 14 days of enteric-coated oral ATP at 150 mg or 225 mg daily against placebo

    no effect, no significant between group treatment effects for any muscular strength parameter

    Not recorded as a finding: the supporting sentence never names the compound

    Overall, we observed no significant between group treatment effects for any muscular strength parameter.

    PMID 15179168 · one of two readings recorded this

  • muscular strength parameters (between groups)

    no effect

    Overall, we observed no significant between group treatment effects for any muscular strength parameter

    PMID 15179168 · one of two readings recorded this

  • one-repetition maximum (1RM), within group change

    increases, p = 0.04

    1RM (6.6%; P < 0.04)

    PMID 15179168 · one of two readings recorded this

  • plasma ATP concentration

    no effect

    Statistical analyses showed no significant between or within group treatment effects for whole blood ATP or plasma ATP concentrations for any treatment condition

    PMID 15179168 · one of two readings recorded this

  • post-Wingate lactate accumulation

    no effect

    We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation

    PMID 15179168 · one of two readings recorded this

  • repetitions to fatigue, set 1 of posttesting, within group change

    increases, p = 0.007

    repetitions to fatigue during set 1 of posttesting (18.5%; P < 0.007)

    PMID 15179168 · one of two readings recorded this

  • total lifting volume at post, within group change

    increases, p = 0.003

    total lifting volume at post (22%; P < 0.003)

    PMID 15179168 · one of two readings recorded this

  • whole blood ATP concentration

    no effect

    Statistical analyses showed no significant between or within group treatment effects for whole blood ATP or plasma ATP concentrations for any treatment condition

    PMID 15179168 · one of two readings recorded this

  • Wingate 30 s anaerobic test parameters (peak power output, total work, average power, post-Wingate lactate) after 14 d of enteric-coated oral ATP 150 mg or 225 mg vs placebo

    no effect, no treatment effects for any Wingate testing parameter

    Not recorded as a finding: the supporting sentence never names the compound

    We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation.

    PMID 15179168 · one of two readings recorded this

  • Wingate average power output (average PO) for 30 s

    no effect

    We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation

    PMID 15179168 · one of two readings recorded this

  • Wingate peak power output (peak PO)

    no effect

    We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation

    PMID 15179168 · one of two readings recorded this

  • Wingate total work

    no effect

    We also did not observe any treatment effects for any Wingate testing parameter including peak PO, total work, average PO for 30 s, or post-Wingate lactate accumulation

    PMID 15179168 · one of two readings recorded this

  • overall assessments of efficacy by patient and investigator

    no effect

    There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ), between-group difference

    no effect, p = 0.2

    The difference between the 2 groups was statistically significant at day 7 (p= 0.02) but not at day 30 (p=0.2)

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ), between-group difference

    decreases, p = 0.02

    The difference between the 2 groups was statistically significant at day 7 (p= 0.02) but not at day 30 (p=0.2)

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ), mean change from baseline

    no effect, p = 0.78

    5.1 +/- 3.9 and 5.0 +/- 4.2 at day 30 (p=0.78)

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ), mean change from baseline

    no effect, p = 0.06

    the mean changes from baseline were 2.8 +/- 3.1 and 2.0 +/- 2.6 at day 7 (p=0.06)

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ)

    decreases

    the mean values dropped from 10.3 +/-2.8 at baseline to 7.5 +/-3.8 (day 7) and 5.2 +/-5.2 (day 30) in the ATP group

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ)

    decreases

    the mean values dropped from 10.3 +/-2.8 at baseline to 7.5 +/-3.8 (day 7) and 5.2 +/-5.2 (day 30) in the ATP group

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ)

    decreases

    from 11.0 +/- 3.5 to 9.1 +/- 4.2 (day 7) and 6.1 +/- 4.3 (day 30) in the placebo group

    PMID 15940776 · one of two readings recorded this

  • Roland-Morris Disability Questionnaire (RDQ)

    decreases

    from 11.0 +/- 3.5 to 9.1 +/- 4.2 (day 7) and 6.1 +/- 4.3 (day 30) in the placebo group

    PMID 15940776 · one of two readings recorded this

  • use of rescue analgesic (dextropropoxyphene and acetaminophen combination tablets)

    decreases, p = 0.04

    there was a significant difference in the use of the rescue analgesic between groups, in favor of ATP (p=0.04)

    PMID 15940776 · one of two readings recorded this

  • visual analog scale pain in subacute low back pain, 90 mg oral ATP once daily against placebo for one month; the primary measure was the Roland-Morris Disability Questionnaire at day 30, and rescue analgesic tablet use was also counted

    no effect, no statistically significant differences between groups at any time point

    Not recorded as a finding: the supporting sentence never names the compound

    There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study.

    PMID 15940776 · one of two readings recorded this

  • visual analog scale pain in subacute low back pain, ATP 90 mg once daily vs placebo for one month

    no effect, no statistically significant differences between groups at any time point

    Not recorded as a finding: the supporting sentence never names the compound

    There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study.

    PMID 15940776 · one of two readings recorded this

  • visual analog scale (VAS) pain

    no effect

    There were no statistically significant differences in the VAS pain and overall assessments of efficacy between groups at any time point during the study

    PMID 15940776 · one of two readings recorded this

  • five-hour total urine volume

    n = 33

    Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)

    PMID 17578566 · one of two readings recorded this

  • five-hour total urine volume

    n = 33

    Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)

    PMID 17578566 · one of two readings recorded this

  • five-hour total urine volume

    n = 33

    Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)

    PMID 17578566 · one of two readings recorded this

  • five-hour total urine volume

    n = 33

    Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)

    PMID 17578566 · one of two readings recorded this

  • urinary L/R excretion ratio versus control

    increases, p = 0.01, n = 33

    Median L/R ratios after indomethacin ingestion with administration of ATP or adenosine remained significantly increased compared to the L/R ratio in the control condition (P < 0.01, Fig. 1)

    PMID 17578566 · one of two readings recorded this

  • urinary L/R excretion ratio versus control

    increases, p = 0.01, n = 33

    Median L/R ratios after indomethacin ingestion with administration of ATP or adenosine remained significantly increased compared to the L/R ratio in the control condition (P < 0.01, Fig. 1)

    PMID 17578566 · one of two readings recorded this

  • urinary L/R excretion ratio

    increases, p = 0.01, n = 33

    After ingestion of indomethacin plus placebo, the median L/R ratio was significantly increased to 0.039 (0.035–0.068; P < 0.01 vs. control)

    PMID 17578566 · one of two readings recorded this

  • urinary L/R excretion ratio

    no effect, p = 0.49, n = 33

    median L/R ratio after ingestion of indomethacin plus adenosine was 0.050 (0.030–0.067; P = 0.49 vs. placebo)

    PMID 17578566 · one of two readings recorded this

  • urinary L/R excretion ratio

    no effect, p = 0.22, n = 33

    Median L/R ratio after ingestion of indomethacin plus ATP was 0.047 (0.033–0.065; P = 0.22 vs. placebo)

    PMID 17578566 · one of two readings recorded this

  • urinary L-rhamnose recovery

    n = 33

    Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)

    PMID 17578566 · one of two readings recorded this

  • urinary L-rhamnose recovery

    n = 33

    Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)

    PMID 17578566 · one of two readings recorded this

  • urinary L-rhamnose recovery

    n = 33

    Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)

    PMID 17578566 · one of two readings recorded this

  • urinary L-rhamnose recovery

    n = 33

    Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery, ATP versus placebo

    no effect, n = 33

    Neither administration of ATP nor of adenosine affected the indomethacin-induced increase in lactulose permeation

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery over 5 h, percent of ingested dose, HPLC with pulsed amperometric detection

    no effect

    Not recorded as a finding: No outcome node for urinary lactulose recovery alone; the node covers only the lactulose/rhamnose ratio. The sentence also pools ATP with adenosine.

    Neither administration of ATP nor of adenosine affected the indomethacin-induced increase in lactulose permeation.

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery versus control

    increases, p = 0.01, n = 33

    Compared to lactulose recovery in the control condition (0.14% (0.08–0.22%)), urinary lactulose recovery was significantly increased by ingestion of indomethacin plus placebo (0.20% (0.11–0.31%); P < 0.01)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery versus control

    increases, p = 0.01, n = 33

    Lactulose recovery after ingestion of capsules with ATP was 0.18% (0.12–0.32%) and was 0.23% (0.11–0.28%) after ingestion of capsules with adenosine; both these values remained significantly increased compared to the control condition (P < 0.01)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery versus control

    increases, p = 0.01, n = 33

    Lactulose recovery after ingestion of capsules with ATP was 0.18% (0.12–0.32%) and was 0.23% (0.11–0.28%) after ingestion of capsules with adenosine; both these values remained significantly increased compared to the control condition (P < 0.01)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery

    n = 33

    Control1 | 0.14 (0.08–0.22) | 4.41 (3.31–5.88) | 298 (182–613)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery

    n = 33

    Indomethacin + adenosine | 0.23 (0.11–0.28)* | 4.52 (3.90–5.26) | 307 (213–563)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery

    n = 33

    Indomethacin + ATP | 0.18 (0.12–0.32)* | 4.12 (3.23–4.89) | 371 (165–518)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose recovery

    n = 33

    Indomethacin + placebo | 0.20 (0.11–0.31)* | 4.60 (3.15–5.91) | 324 (193–493)

    PMID 17578566 · one of two readings recorded this

  • urinary lactulose/rhamnose (L/R) excretion ratio

    n = 33

    Median L/R ratio (g/g) in the control condition (no indomethacin, no ATP/adenosine) was 0.032 (interquartile range: 0.022–0.044)

    PMID 17578566 · one of two readings recorded this

  • blood and plasma ATP concentration after 28 days of daily enteric-coated oral ATP (0, 250, 1250 or 5000 mg)

    no effect, no change in blood or plasma ATP concentrations after 4 weeks

    Not recorded as a finding: this platform holds no node for the endpoint

    ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations.

    PMID 21129239 · one of two readings recorded this

  • blood and plasma ATP concentrations after 28 days of daily oral enteric-coated ATP pellets at 0, 250, 1250 or 5000 mg per day; plasma uric acid after a 5000 mg ATP dose was also measured

    no effect, no change in blood or plasma ATP concentrations after 4 weeks of supplementation

    Not recorded as a finding: this platform holds no node for the endpoint

    ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations.

    PMID 21129239 · one of two readings recorded this

  • blood ATP concentration

    no effect

    ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations

    PMID 21129239 · one of two readings recorded this

  • liver and kidney parameters (safety)

    no effect

    Prolonged administration of ATP was safe as evidenced from liver and kidney parameters

    PMID 21129239 · one of two readings recorded this

  • plasma ATP concentration

    no effect

    ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations

    PMID 21129239 · one of two readings recorded this

  • plasma uric acid

    increases

    Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of 5000 mg of ATP

    PMID 21129239 · one of two readings recorded this

  • ADP formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • ADP formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • AMP formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • AMP formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • ATP released from pellets after 120 min in 0.1 N HCl (dissolution test)

    After staying for 120 min in 0.1 N HCl, less than 5% ATP (5.0 ± 0.6% for the proximal-release pellets and 3.4 ± 0.4% for the distal-release pellets) was released from the pellets

    PMID 22510240 · one of two readings recorded this

  • ATP released from pellets after 120 min in 0.1 N HCl (dissolution test)

    After staying for 120 min in 0.1 N HCl, less than 5% ATP (5.0 ± 0.6% for the proximal-release pellets and 3.4 ± 0.4% for the distal-release pellets) was released from the pellets

    PMID 22510240 · one of two readings recorded this

  • plasma lithium AUC, ATP-containing versus placebo proximal-release pellets

    decreases, p = 0.001

    the lithium AUC was significantly lower in the ATP-containing pellets than in the placebo-containing ones (P = 0.001)

    PMID 22510240 · one of two readings recorded this

  • plasma lithium AUC, proximal-release versus distal-release ATP pellets

    increases, p = 0.001

    the proximal-release pellets caused a significantly higher increase in plasma lithium than the distal-release pellets (P = 0.001)

    PMID 22510240 · one of two readings recorded this

  • plasma lithium AUC (release marker)

    ATP (420 min) | 25.4 ± 5.7 d,e | 0.30 ± 0.03 | 240 | 65174 ± 7985 f

    PMID 22510240 · one of two readings recorded this

  • plasma lithium AUC (release marker)

    Placebo (420 min) | 0.9 ± 1.1 | 0.20 ± 0.02 | n.a. | 117914 ± 15021 f

    PMID 22510240 · one of two readings recorded this

  • plasma lithium AUC (release marker)

    ATP (420 min) | 3.2 ± 1.4 | 0.22 ± 0.02 | 390 | 12575 ± 2832 f

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    no effect

    Administration of ATP by distal-release pellets did not lead to a significantly increased uric acid AUC, compared to placebo

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    increases, p = 0.003

    Compared to placebo, the uric acid AUC increased significantly when ATP was administered by proximal-release pellets (P = 0.003) or by naso-duodenal tube (P = 0.001)

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    increases, p = 0.001

    Compared to placebo, the uric acid AUC increased significantly when ATP was administered by proximal-release pellets (P = 0.003) or by naso-duodenal tube (P = 0.001)

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    no effect

    ATP (270 min) | 1.7 ± 1.1 | n.a. | n.a. | n.a.

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    no effect

    ATP (420 min) | 3.2 ± 1.4 | 0.22 ± 0.02 | 390 | 12575 ± 2832 f

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    increases

    ATP (270 min) | 16.1 ± 3.0 | n.a. | n.a. | n.a.

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    increases

    ATP (420 min) | 25.4 ± 5.7 d,e | 0.30 ± 0.03 | 240 | 65174 ± 7985 f

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    increases

    ATP (270 min) | 19.6 ± 4.4 a,b,c | 0.31 ± 0.03 | 135 | n.a.

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    Placebo (270 min) | 0.8 ± 0.9 | n.a. | n.a. | n.a.

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    Placebo (420 min) | 0.9 ± 1.1 | 0.20 ± 0.02 | n.a. | 117914 ± 15021 f

    PMID 22510240 · one of two readings recorded this

  • uric acid AUC (blood)

    Placebo (270 min) | −0.4 ± 0.4 | 0.21 ± 0.03 | n.a. | n.a.

    PMID 22510240 · one of two readings recorded this

  • uric acid formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • uric acid formed from ATP during dissolution

    ATP was partially broken down to ADP (8.6% for proximal-release pellets, 7.0% for distal-release pellets), AMP (1.0 and 0.7%, respectively), and uric acid (4.0 and 2.5%, respectively)

    PMID 22510240 · one of two readings recorded this

  • whole-blood ATP concentration after a single 5000 mg oral ATP dose, HPLC, AUC over 4.5-7 h

    no effect, no statistically significant differences between placebo and ATP for any type of administration (data not shown)

    Not recorded as a finding: this platform holds no node for the endpoint

    HPLC analysis of the whole blood showed that ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration (data not shown).

    PMID 22510240 · one of two readings recorded this

  • whole-blood ATP concentration over time, HPLC with UV detection, after a single 5000 mg dose of enteric-coated ATP pellets or ATP via naso-duodenal tube against placebo; whole-blood uric acid AUC by the same HPLC method was also measured

    no effect, no statistically significant differences between placebo and ATP for any administration type (data not shown)

    Not recorded as a finding: this platform holds no node for the endpoint

    HPLC analysis of the whole blood showed that ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration (data not shown).

    PMID 22510240 · one of two readings recorded this

  • whole-blood ATP concentration

    no effect

    ATP concentrations were stable over time, and that there were no statistically significant differences between placebo and ATP supplements for any type of administration

    PMID 22510240 · one of two readings recorded this

  • pain scores at postoperative days 7, 14, 21 and 28, quadriceps strength and total opioid consumption after total knee arthroplasty, 120 mg oral ATP daily against placebo for 4 weeks

    Not recorded as a finding: the paper never states the instrument the node requires

    Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected.

    PMID 24813646 · one of two readings recorded this

  • pain scores

    unclear

    Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected

    PMID 24813646 · one of two readings recorded this

  • quadriceps strength

    unclear

    Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected

    PMID 24813646 · one of two readings recorded this

  • total opioid consumption

    unclear

    Significant differences in quadriceps strength, pain scores at postoperative days 7, 14, 21, and 28 and total opioid consumption were detected

    PMID 24813646 · one of two readings recorded this

  • muscle activation

    no effect

    No group by time interaction was observed for muscle activation

    PMID 28080323 · one of two readings recorded this

  • muscle excitability in later bouts

    no effect

    ATP supplementation prevented the decline in later bouts

    PMID 28080323 · one of two readings recorded this

  • muscle excitability

    decreases, p = 0.02

    muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)

    PMID 28080323 · one of two readings recorded this

  • muscle excitability

    decreases, p = 0.02

    muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)

    PMID 28080323 · one of two readings recorded this

  • muscle excitability

    decreases, p = 0.02

    muscle excitability significantly decreased in later bouts 8, 9, and 10 in the placebo group (-30.5, -28.3, and -27.9%, respectively; p < 0.02)

    PMID 28080323 · one of two readings recorded this

  • postexercise ADP level

    no effect, p = 0.05

    Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)

    PMID 28080323 · one of two readings recorded this

  • postexercise AMP level

    no effect, p = 0.05

    Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)

    PMID 28080323 · one of two readings recorded this

  • postexercise ATP level

    no effect, p = 0.05

    Oral ATP supplementation prevented a drop in ATP, adenosine-5'-diphosphate (ADP), and adenosine-5'-monophosphate (AMP) levels postexercise (p < 0.05)

    PMID 28080323 · one of two readings recorded this

  • Wingate peak power

    increases

    ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%)

    PMID 28080323 · one of two readings recorded this

  • Wingate peak power

    increases

    ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%)

    PMID 28080323 · one of two readings recorded this

  • Wingate test peak power across repeated sprint bouts, 400 mg oral ATP disodium salt against placebo for 2 weeks; also muscle excitability (ratio of power output to muscle activation) and blood ATP, ADP and AMP after exercise

    increases, within-arm change from baseline: bout 8 +18.3%, bout 10 +16.3%

    Not recorded as a finding: the result compares a group with itself, not with a control

    ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%).

    PMID 28080323 · one of two readings recorded this

  • Wingate test peak power across ten repeated sprint bouts after 2 weeks of 400 mg oral ATP or placebo

    increases, bout 8: +18.3%, bout 10: +16.3% versus baseline in the ATP group

    Not recorded as a finding: the result compares a group with itself, not with a control

    ATP significantly increased Wingate peak power in later bouts compared to baseline (bout 8: +18.3%, bout 10: +16.3%).

    PMID 28080323 · one of two readings recorded this

  • blood lactate

    no effect

    There were no differences between conditions for lactate and blood pressure

    PMID 29045315 · one of two readings recorded this

  • blood pressure

    no effect

    There were no differences between conditions for lactate and blood pressure

    PMID 29045315 · one of two readings recorded this

  • heart rate

    increases, p = 0.001

    Heart rate was higher at set-4 for ATP compared with placebo (p < 0.001)

    PMID 29045315 · one of two readings recorded this

  • oxygen consumption during exercise

    increases, p = 0.021

    oxygen consumption during exercise was greater for ATP (p = 0.021)

    PMID 29045315 · one of two readings recorded this

  • total weight lifted in 4 sets of half-squats to momentary muscular failure at 80% of 1RM, 400 mg oral ATP against placebo

    increases, p = 0.005

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    The total weight lifted were higher for the ATP condition compared with placebo (Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005).

    PMID 29045315 · one of two readings recorded this

  • total weight lifted (kg) over 4 sets of half-squats to momentary muscular failure at 80% of 1RM

    increases, p = 0.005

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    The total weight lifted were higher for the ATP condition compared with placebo (Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005).

    PMID 29045315 · one of two readings recorded this

  • total weight lifted

    increases, p = 0.005

    (Placebo = 3,995.7 ± 1,137.8, ATP = 4,967.4 ± 1,497.9 kg; p = 0.005)

    PMID 29045315 · one of two readings recorded this

  • diastolic blood pressure across recovery

    no effect, p = 0.05

    For DBP (mmHg), there was no main effect of time, interaction and conditions (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • diastolic blood pressure after exercise, automatic Omron cuff monitor

    no effect, no main effect of time, interaction or conditions

    Not recorded as a finding: The only sentence is agentless and never names ATP; the subject lives in the previous sentence.

    For DBP (mmHg), there was no main effect of time, interaction and conditions (P>0.05).

    PMID 30276192 · one of two readings recorded this

  • exercise intensity

    no effect

    For exercise intensity, no significant difference was observed between trials

    PMID 30276192 · one of two readings recorded this

  • heart rate during recovery

    no effect

    For HR (bpm) there was a main effect of time (F=19.249, P<0.001, η2=0.68) with higher HR for placebo and ATP in relation to rest, however, no significant difference were observed between trials

    PMID 30276192 · one of two readings recorded this

  • HF power delta (recovery minus rest)

    unclear, p = 0.05

    there was a trend to a significant difference in the HFmsec2 (ATP=5.1±77.6 msec2 vs. Placebo= −55.3±80.5 msec2, P=0.05)

    PMID 30276192 · one of two readings recorded this

  • HF power (msec2) during recovery

    no effect, p = 0.05

    Regarding frequency domain (LFmsec2 and HFmsec2), there were no significant difference during recovery (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • HFnu during recovery

    no effect, p = 0.05

    For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • LF/HF ratio during recovery

    no effect, p = 0.05

    For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • LF power delta (recovery minus rest)

    increases, p = 0.028

    LFmsec2 was statistically lower for placebo in relation to ATP (ATP=−19.9±122.7 msec2 vs. placebo=−94.2± 200.3 msec2, P=0.028)

    PMID 30276192 · one of two readings recorded this

  • LF power (msec2) during recovery

    no effect, p = 0.05

    Regarding frequency domain (LFmsec2 and HFmsec2), there were no significant difference during recovery (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • LFnu during recovery

    no effect, p = 0.05

    For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • RMSSD delta (recovery minus rest)

    increases, p = 0.009

    For RMSSD, there was a significant greater values for ATP compared to placebo (ATP=2.2±7.2 msec vs. placebo=−4.7±7.6 msec; P=0.009)

    PMID 30276192 · one of two readings recorded this

  • RMSSD during recovery

    increases, p = 0.027

    For RMSSD, there was statistically significant difference during recovery (F=4.917, P=0.020, η2=0.35), with significant higher RMSSD for ATP compared to placebo (P=0.027)

    PMID 30276192 · one of two readings recorded this

  • SDNN delta (recovery minus rest)

    increases, p = 0.014

    delta analysis showed significant higher SDNN for ATP (ATP=3.1±10.8 msec vs. placebo=−2.9±8.5 msec, P=0.014)

    PMID 30276192 · one of two readings recorded this

  • SDNN during recovery

    increases, p = 0.041

    When analyzed SDNN, there was no statistically significant difference (F=2.414, P=0.118, η2=0.21), however, Bonferroni post hoc demonstrated significant greater SNDD in the ATP conditions compared to placebo (P=0.041)

    PMID 30276192 · one of two readings recorded this

  • systolic blood pressure across recovery, condition effect

    no effect, p = 0.05

    Regarding SBP (mmHg), there was a main effect of time (F=12.649, P<0.001, η2=0.55), but no difference between conditions and interaction were verified (P>0.05)

    PMID 30276192 · one of two readings recorded this

  • systolic blood pressure change 20 min after exercise (post-20 minus rest), automatic Omron monitor, supine after exercise

    decreases, delta SBP ATP -13.18 +/- 8.3 vs placebo -6.1 +/- 9.9 mmHg, p = 0.006

    Not recorded as a finding: Node systolic-blood-pressure-unspecified-setting is for sources that do not record acquisition conditions; here the post-exercise supine protocol is recorded, and the office node requires a seated clinic reading. Near miss on setting.

    However, when analyzed the delta (Δ=post-20 min minus rest), there was a significant lower SBP for ATP compared to placebo (ATP= −13.18±8.3 mm/Hg vs. placebo=−6.1±9.9 mm/Hg, P=0.006).

    PMID 30276192 · one of two readings recorded this

  • systolic blood pressure delta (post-20 min minus rest)

    decreases, p = 0.006

    there was a significant lower SBP for ATP compared to placebo (ATP= −13.18±8.3 mm/Hg vs. placebo=−6.1±9.9 mm/Hg, P=0.006)

    PMID 30276192 · one of two readings recorded this

  • fatigue level as exercise progressed

    decreases

    it was able to reduce fatigue levels as the exercise progressed

    PMID 38193939 · one of two readings recorded this

  • knee extension and flexion muscle strength indicators and resistance to fatigue over five isokinetic sets at 60 degrees per second, Biodex 4.0 isokinetic dynamometer, 400 mg Peak ATP against placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    An acute dose of 400 mg of ATP did not improve the volunteers' muscle strength indicators, but it was able to reduce fatigue levels as the exercise progressed, enabling greater performance for longer.

    PMID 38193939 · one of two readings recorded this

  • muscle strength indicators

    no effect

    Acute supplementation was unable to achieve significant improvements in muscle strength indicators

    PMID 38193939 · one of two readings recorded this